NASDAQ: GPCR - Structure Therapeutics Inc.

Rentabilité sur six mois: +5.4%
Secteur: Healthcare

Calendrier des promotions Structure Therapeutics Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Plus de détails
The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Цена ао 41.15
EBITDA -1.6E-5
Число акций ао 0.03673 млрд
EV/EBITDA 1.01
ISIN US86366E1064
Сайт https://structuretx.com
P/BV 2.88
Валюта usd
IPO date 2023-02-03
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Changement de prix par jour: +3.08% (39.92)
Changement de prix par semaine: +4.42% (39.41)
Changement de prix par mois: -6.52% (44.02)
Changement de prix sur 3 mois: +7.41% (38.31)
Changement de prix sur six mois: +5.4% (39.04)
Changement de prix par an: -41.21% (70)
Evolution des prix depuis le début de l'année: -35.87% (64.17)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 2.88 6
P/E 0 0
EV/EBITDA -11.6 0
Total: 2.75

Efficacité

Nom Signification Grade
ROA, % -18.58 0
ROE, % -19.77 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0536 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 635753.06 10
Rentabilité EPS, % 384390.44 10
Total: 8
Plus de détails

Établissements Volume Partager, %
Wellington Management Group, LLP 4372326 9.38
FMR, LLC 4034584 8.66
Driehaus Capital Management, LLC 2599079 5.58
Avoro Capital Advisors LLC 2333333 5.01
Federated Hermes, Inc. 2267206 4.87
Tcg Crossover Management, Llc 2109584 4.53
Adage Capital Partners GP L.L.C. 1756918 3.77
Price (T.Rowe) Associates Inc 1679436 3.6
Janus Henderson Group PLC 1544416 3.31
T. Rowe Price Investment Management, Inc. 1312195 2.82

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
Principal Healthcare Innovators ETF 0.24233 631.79771324797 0.8416
Future Tech ETF 0.24233 412.888593871 0.8416



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Raymond C. Stevens Ph.D. CEO & Director 890.38k 1964 (60 années)
Dr. Yingli Ma Ph.D. Chief Technology Officer 497.58k 1974 (50 années)
Mr. Jun S. Yoon Co- Founder, CFO & Secretary 627.64k 1978 (46 années)
Dr. Xichen Lin Ph.D. Chief Scientific Officer N/A 1974 (50 années)
Mr. Tony Peng Senior Vice President of Legal N/A
Mr. Bob Gatmaitan Senior Vice President of People N/A
Dr. Hui Lei Ph.D. Senior Vice President of Chemistry N/A
Dr. Fang Zhang Ph.D. Executive VP & Head of Biology N/A
Ms. Lani Ibarra Senior Vice President of Clinical Development Operations N/A
Dr. Xinglong Jiang Ph.D. Senior Vice President of Preclinical Development

Adresse: United States, South San Francisco. CA, 611 Gateway Boulevard - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://structuretx.com